<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Institutional Vote</th>
</tr>
</thead>
</table>
| NSCL-18                   | Internal request: Review the data for alectinib for the treatment of patients with metastatic ALK-positive Non-Small Cell Lung Cancer who have progressed on or are intolerant to crizotinib. External request: Submission from Genentech requesting consideration of the available data on the use of alectinib in ALK+ NSCLC patients for inclusion in the NCCN Guidelines. | Based upon review of the data in the noted references, the panel consensus was to add alectinib as a category 2A recommendation for the following indications:  
  - Asymptomatic progression  
  - Symptomatic progression with brain metastases  
  - Symptomatic progression and multiple systemic metastasis  
  - Progression on subsequent therapy | 18 0 0 9 |
| NSCL-18                   | Internal request: Review the data for ceritinib for the treatment of patients with metastatic ALK-positive Non-Small Cell Lung Cancer who have progressed on crizotinib and have symptomatic brain metastases. | Based upon review of the data in the noted reference, the panel consensus was to add ceritinib as a category 2A recommendation for the following indication:  
| NSCL-19, NSCL-20          | External request: Submission from Eli Lilly requesting ramucirumab + docetaxel for the treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy, regardless of histology, be listed as a preferred or superior treatment choice over docetaxel alone. | Based upon review of the data in the noted references, the panel consensus was to not change the current listing for ramucirumab + docetaxel. | 0 18 0 9 |
Based upon review of the data in the noted references, the panel consensus was to add the combination regimen of cisplatin/gemcitabine/necitumumab as a first-line therapy option for patients with squamous cell carcinoma as a category 3 recommendation. The Panel noted concerns over toxicity versus benefit.

- See Submission for references.
- Prescribing Information for Necitumumab.

| Internal request: Review the data for the combination regimen of cisplatin/gemcitabine/necitumumab for the first-line treatment of patients with metastatic squamous cell carcinoma. | External request: Submission from Eli Lilly requesting that necitumumab be considered for inclusion in the NCCN Guidelines as a category 1 recommendation for the first-line treatment of metastatic squamous NSCLC in combination with gemcitabine and cisplatin. | 3 | 15 | 0 | 9 |